m2
341 Results
Ricerca avanzata
Visualizzare
-
-
Optimization and Process Simulation | Ultrafiltration Learning Center | Biopharmaceutical Manufacturing | Merck
Before you implement an ultrafiltration step, define these key operation parameters: Crossflow rate, Transmembrane pressure (TMP), Filtrate control, Membrane area and Diafiltration design. -
Activated Carbon Tutorial | Water Purification | Merck
Activated carbon is made of organic material porous particulates containing a maze of small pores, which account for the substance's highly developed surface. -
Press Release: Merck Introduces Parteck® SLC, Silica-based Excipient for Enhanced Drug Solubility and Bioavailability
Merck, today introduced Parteck® SLC, a new excipient with a unique surface structure that delivers significantly increased loadability for active pharmaceutical ingredients (API). -
LiChrosorb® HPLC Columns and Sorbents | Analytics and Sample Preparation | Merck
LiChrosorb® HPLC packing materials consist of fully porous irregular particles available as analytical or semi-preparative LiChroCART® and Hibar® RT columns. -
LiChrosorb® RP-18 (5 µm) | Analytical and Sample Preparation | Merck
LiChrosorb® RP-18 (5 µm) columns and sorbents for reversed-phase HPLC are classified as L1 columns, fully compliant with US Pharmacopoeia specifications. -
Press Release: Merck Receives Recertification of GMP Compliance for Biodevelopment Centre in Martillac, France
Merck, today announced that its Biodevelopment Centre in Martillac, France, has been recertified by the French National Agency for Medicines and Health Products Safety (ANSM), the competent authority of France. -
Preclinical | Emerging Biotech | Merck
Pre-clinical testing establishes that the target compound is safe and effective - before it can be tested in humans. -
Phase III | Emerging Biotech | Merck
Phase III trials use a much larger patient population - in the thousands - to give statistical weight to results that can prove safety and efficacy. -
Phase I | Emerging Biotech | Merck
Phase I means you've filed your IND and are ready to begin evaluating your drug in humans.